Key result
Serelaxin shows unique hemodynamic effects linked to organ protection and better outcomes in acute heart failure.
Answers are grounded in this paper and cite their sources.
The availability of highly purified recombinant human relaxin, serelaxin, has allowed clinical trials to be conducted in several indications and the elucidation of its pharmacology in human subjects. These studies have demonstrated that serelaxin has unique haemodynamic properties that are likely to contribute to organ protection and long-term outcome benefits in acute heart failure. Clinical observations support its consideration for therapeutic use in other patient populations, including those with chronic heart failure, coronary artery disease, portal hypertension and acute renal failure. LINKED ARTICLES: This article is part of a themed section on Recent Progress in the Understanding of Relaxin Family Peptides and their Receptors. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.10/issuetoc.
No takes yet. Share an insight, caveat, or question.
Elaine Unemori (2016) conducted a review in Acute heart failure. Serelaxin was evaluated. Serelaxin demonstrates unique hemodynamic properties that likely contribute to organ protection and long-term outcome benefits in acute heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: